查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951789

气喘生物製药市场分析及预测（至2035年）：依类型、产品、应用、最终用户、技术、设备、阶段、成分、实施类型及解决方案划分

Asthma Biologics Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Device, Stage, Component, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 348 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计气喘生物製药市场将从2024年的74亿美元成长到2034年的235亿美元，复合年增长率约为12.3%。气喘生物製药市场涵盖了透过调节特定免疫路径来治疗重度气喘的先进疗法。这些生物製药产品（通常是单株抗体）提供个人化治疗方案，可减少气喘发作频率并提高患者的生活品质。气喘盛行率上升、生物技术进步和医疗保健支出增加是推动市场成长的主要因素。新型生物製药的研发、策略合作和适应症的拓展等关键趋势预计将推动市场强劲成长。

由于气喘盛行率不断上升以及对先进治疗方法的需求日益增长，气喘生物製药市场正经历显着增长。单株抗体细分市场是成长最快的子细分市场，这得益于其能够有效靶向气喘相关的特定路径。尤其值得关注的是抗IgE和抗IL-5生物製药，它们能够为重度气喘患者提供标靶症状缓解。白细胞介素抑制剂细分市场也紧随其后，这反映出其良好的临床疗效使其应用日益广泛。针对特定细胞激素和受体的创新治疗方法正在蓬勃发展，为患者提供个人化的治疗方案。研发活动也集中在开发具有更高疗效和安全性的新型生物製药。先进诊断工具的整合能够达到精准的患者分层，进而优化治疗效果。此外，製药公司之间的策略联盟和伙伴关係正在推动创新并加速市场渗透。随着医疗基础设施的改善和患者意识的提高，预计气喘治疗领域对生物製药的需求将会增加。

市场区隔
类型 单株抗体、白细胞介素抑制剂、抗IgE、抗IL-5、抗IL-4
产品 吸入器、注射、口服锭、雾化器
目的 重度气喘、中度气喘、儿童气喘、成人气喘
最终用户 医院、诊所、居家医疗、研究机构、製药公司
科技 生物技术、基因组学和蛋白​​质组学
装置 携带式设备、固定式设备、穿戴式装置
步 临床试验、商业化与在研发线产品
成分 活性成分、添加物、稳定剂
实施表格 本机部署、云端部署
解决方案 患者管理、药物输送系统

气喘生物製药市场的特征是市场份额、定价策略和产品创新之间存在着动态的相互作用。现有企业利用其广泛的产品系列和策略性定价策略来维持竞争优势并主导市场。然而，新参与企业正以创新的生物製药疗法为市场注入新的活力，进一步加剧了竞争格局。定价仍然是关键因素，受到生产复杂性和监管路径的影响。近期推出的产品凸显了该行业为满足未被满足的需求、提高治疗效果和改善患者预后所做的努力。竞争基准分析显示，主要市场参与企业之间的竞争异常激烈，每家企业都在追求技术优势和市场渗透率。监管影响，尤其是在北美和欧洲，对市场准入和合规标准起着至关重要的作用。专利到期和生物相似药的推出加剧了竞争，并进一步塑造了市场格局。分析结果表明，随着企业寻求巩固其市场地位，策略联盟和收购十分普遍。在个人化医疗的进步和全球气喘盛行率不断上升的推动下，该市场的成长前景十分乐观。

主要趋势和驱动因素：

受个人化医疗的进步和全球气喘患者数量不断增长的推动，气喘生物製药市场正经历强劲成长。关键趋势包括生物製药与数位健康技术的融合，有助于改善患者管理并提高治疗依从性。单株抗体作为首选治疗方案的出现，推动了市场向标靶治疗的转变，有助于改善患者预后并减少病情恶化。推动该市场发展的因素包括气喘认知度和诊断率的提高，以及医疗费用支出的显着增长。未被满足的医疗需求和传统气喘治疗方法的限制进一步推动了对创新治疗方法的需求。此外，监管部门对生物製药的支持和加速核准流程正在加速其市场准入和应用。新兴市场蕴藏大量机会，这些市场的医疗基础设施不断完善，生物製药的可近性也不断扩大。专注于开发经济高效且易于获取的治疗方法的公司，将占据有利地位，从而获得可观的市场份额。此外，生物技术公司与医疗保健机构之间的合作正在促进创新，并扩大气喘生物製药的覆盖范围。在技​​术进步和对以患者为中心的护理日益重视的推动下，市场预计将持续成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 白细胞介素抑制剂
    • 抗IgE
    • 抗IL-5
    • 抗IL-4
  • 市场规模及预测：依产品划分
    • 吸入器
    • 注射
    • 口服锭剂
    • 喷雾器
  • 市场规模及预测：依应用领域划分
    • 重度气喘
    • 中度气喘
    • 儿童气喘
    • 成人气喘
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 居家医疗
    • 研究所
    • 製药公司
  • 市场规模及预测：依技术划分
    • 生物技术
    • 基因组学
    • 蛋白质体学
  • 市场规模及预测：依设备划分
    • 携带式装置
    • 固定设备
    • 穿戴式装置
  • 市场规模及预测：依阶段划分
    • 临床试验
    • 商业化
    • 研发线产品
  • 市场规模/预测：依成分划分
    • 活性成分
    • 添加剂
    • 稳定器
  • 市场规模及预测：依实施类型划分
    • 本地部署
    • 基于云端的
  • 市场规模及预测：按解决方案划分
    • 病患管理
    • 药物输送系统

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Circassia Pharmaceuticals
  • Aimmune Therapeutics
  • DBV Technologies
  • Allakos
  • Kymab
  • Astra Zeneca
  • Amgen
  • Teva Pharmaceutical Industries
  • GSK
  • Regeneron Pharmaceuticals
  • Sanofi
  • Novartis
  • Chiesi Farmaceutici
  • ALK-Abello
  • Mabtech
  • Genentech
  • Boehringer Ingelheim
  • Biogen
  • Alkermes
  • Innovent Biologics

第九章：关于我们

简介目录
Product Code: GIS26164

Asthma Biologics Market is anticipated to expand from $7.4 billion in 2024 to $23.5 billion by 2034, growing at a CAGR of approximately 12.3%. The Asthma Biologics Market encompasses advanced therapeutic solutions targeting severe asthma by modulating specific immune pathways. These biologics, often monoclonal antibodies, offer personalized treatment options, reducing exacerbations and improving patient quality of life. The market is driven by rising asthma prevalence, advancements in biotechnology, and increased healthcare expenditure. Key trends include the development of novel biologics, strategic collaborations, and expanding indications, positioning the market for robust growth.

The Asthma Biologics Market is experiencing significant growth, driven by the rising prevalence of asthma and the need for advanced treatment options. The monoclonal antibodies segment is the top-performing sub-segment, owing to its effectiveness in targeting specific pathways involved in asthma. Anti-IgE and anti-IL-5 biologics are particularly noteworthy, as they offer targeted relief for severe asthma patients. The interleukin inhibitors segment follows closely, reflecting their growing adoption due to promising clinical outcomes. Innovative therapies targeting specific cytokines and receptors are gaining momentum, offering personalized treatment approaches. The market is also witnessing increased research and development activities focused on novel biologics, enhancing treatment efficacy and safety profiles. The integration of advanced diagnostic tools is facilitating precise patient stratification, optimizing therapeutic outcomes. Moreover, strategic collaborations and partnerships among pharmaceutical companies are fostering innovation and accelerating market penetration. The demand for biologics in asthma management is set to rise, driven by improved healthcare infrastructure and patient awareness.

Market Segmentation
TypeMonoclonal Antibodies, Interleukin Inhibitors, Anti-IgE, Anti-IL-5, Anti-IL-4
ProductInhalers, Injectables, Oral Tablets, Nebulizers
ApplicationSevere Asthma, Moderate Asthma, Pediatric Asthma, Adult Asthma
End UserHospitals, Clinics, Homecare Settings, Research Institutes, Pharmaceutical Companies
TechnologyBiotechnology, Genomics, Proteomics
DevicePortable Devices, Stationary Devices, Wearable Devices
StageClinical Trials, Commercialized, Pipeline Products
ComponentActive Ingredients, Excipients, Stabilizers
DeploymentOn-premise, Cloud-based
SolutionsPatient Management, Drug Delivery Systems

The Asthma Biologics Market is characterized by a dynamic interplay of market share, pricing strategies, and product innovations. Established players dominate, leveraging their extensive portfolios and strategic pricing to maintain competitive advantage. New entrants, however, are invigorating the market with novel biologic therapies, fostering a competitive landscape. Pricing remains a pivotal factor, influenced by manufacturing complexities and regulatory pathways. Recent product launches underscore the industry's commitment to addressing unmet clinical needs, offering enhanced therapeutic efficacy and patient outcomes. Competition benchmarking reveals a robust rivalry among key market participants, with each striving for technological superiority and market penetration. Regulatory influences, particularly in North America and Europe, are pivotal, dictating market entry and compliance standards. The landscape is further shaped by patent expirations and biosimilar introductions, intensifying competition. Analytical insights indicate that strategic alliances and acquisitions are prevalent, as companies seek to bolster their market positions. The market trajectory is promising, driven by advancements in personalized medicine and increasing prevalence of asthma globally.

Geographical Overview:

The Asthma Biologics Market is experiencing notable expansion across various regions, each exhibiting unique growth dynamics. North America remains at the forefront, driven by advanced healthcare infrastructure and high prevalence of asthma. The region's strong focus on research and development fosters innovation in biologic therapies, enhancing market growth. Europe follows closely, with significant investments in healthcare and a rising demand for advanced asthma treatments. The region's emphasis on improving patient outcomes and quality of life further propels the market. In Asia Pacific, the market is expanding rapidly, supported by increasing asthma prevalence and growing healthcare expenditure. Emerging economies such as China and India are witnessing substantial growth, attributed to improving healthcare access and rising awareness of biologic treatments. Latin America and the Middle East & Africa present emerging growth pockets. These regions are increasingly recognizing the potential of biologics in addressing asthma, driving investments and fostering market development.

Global tariffs and geopolitical tensions are significantly influencing the Asthma Biologics Market, particularly in East Asia. In Japan and South Korea, the focus is on bolstering domestic production capabilities to mitigate reliance on foreign biologics, spurred by potential tariff escalations. China's strategy includes enhancing its biopharmaceutical sector through substantial investment in R&D and fostering local innovation, a response to both trade restrictions and the need for self-sufficiency. Taiwan, while a pivotal player in biologics manufacturing, faces geopolitical vulnerabilities due to its proximity to China. Globally, the asthma biologics sector is experiencing robust growth, driven by rising asthma prevalence and innovation in biologic therapies. By 2035, the market is expected to thrive on strategic regional collaborations and resilient supply chains, despite potential disruptions from Middle East conflicts affecting energy prices and logistics.

Key Trends and Drivers:

The Asthma Biologics Market is experiencing robust growth, driven by advancements in personalized medicine and increased prevalence of asthma worldwide. Key trends include the integration of biologics with digital health technologies, facilitating better patient management and adherence to treatment regimens. The rise of monoclonal antibodies as a preferred treatment option underscores the market's shift towards targeted therapies, enhancing patient outcomes and reducing exacerbations. Drivers of this market include the growing awareness and diagnosis rates of asthma, coupled with a significant rise in healthcare expenditure. The demand for innovative therapies is further propelled by unmet medical needs and the limitations of traditional asthma treatments. Additionally, regulatory support and expedited approval processes for biologics are accelerating market entry and adoption. Opportunities are abundant in emerging markets where healthcare infrastructure is improving, and access to biologics is expanding. Companies that focus on developing cost-effective and accessible treatment options are well-positioned to capture significant market share. Furthermore, partnerships and collaborations between biotech firms and healthcare providers are fostering innovation and expanding the reach of asthma biologics. The market is poised for sustained growth, driven by technological advancements and an increasing focus on patient-centric care.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Interleukin Inhibitors
    • 4.1.3 Anti-IgE
    • 4.1.4 Anti-IL-5
    • 4.1.5 Anti-IL-4
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Inhalers
    • 4.2.2 Injectables
    • 4.2.3 Oral Tablets
    • 4.2.4 Nebulizers
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Severe Asthma
    • 4.3.2 Moderate Asthma
    • 4.3.3 Pediatric Asthma
    • 4.3.4 Adult Asthma
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Homecare Settings
    • 4.4.4 Research Institutes
    • 4.4.5 Pharmaceutical Companies
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Biotechnology
    • 4.5.2 Genomics
    • 4.5.3 Proteomics
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Portable Devices
    • 4.6.2 Stationary Devices
    • 4.6.3 Wearable Devices
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Clinical Trials
    • 4.7.2 Commercialized
    • 4.7.3 Pipeline Products
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Active Ingredients
    • 4.8.2 Excipients
    • 4.8.3 Stabilizers
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-premise
    • 4.9.2 Cloud-based
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Patient Management
    • 4.10.2 Drug Delivery Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Device
      • 5.2.1.7 Stage
      • 5.2.1.8 Component
      • 5.2.1.9 Deployment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Device
      • 5.2.2.7 Stage
      • 5.2.2.8 Component
      • 5.2.2.9 Deployment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Device
      • 5.2.3.7 Stage
      • 5.2.3.8 Component
      • 5.2.3.9 Deployment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Device
      • 5.3.1.7 Stage
      • 5.3.1.8 Component
      • 5.3.1.9 Deployment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Device
      • 5.3.2.7 Stage
      • 5.3.2.8 Component
      • 5.3.2.9 Deployment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Device
      • 5.3.3.7 Stage
      • 5.3.3.8 Component
      • 5.3.3.9 Deployment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Device
      • 5.4.1.7 Stage
      • 5.4.1.8 Component
      • 5.4.1.9 Deployment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Device
      • 5.4.2.7 Stage
      • 5.4.2.8 Component
      • 5.4.2.9 Deployment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Device
      • 5.4.3.7 Stage
      • 5.4.3.8 Component
      • 5.4.3.9 Deployment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Device
      • 5.4.4.7 Stage
      • 5.4.4.8 Component
      • 5.4.4.9 Deployment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Device
      • 5.4.5.7 Stage
      • 5.4.5.8 Component
      • 5.4.5.9 Deployment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Device
      • 5.4.6.7 Stage
      • 5.4.6.8 Component
      • 5.4.6.9 Deployment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Device
      • 5.4.7.7 Stage
      • 5.4.7.8 Component
      • 5.4.7.9 Deployment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Device
      • 5.5.1.7 Stage
      • 5.5.1.8 Component
      • 5.5.1.9 Deployment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Device
      • 5.5.2.7 Stage
      • 5.5.2.8 Component
      • 5.5.2.9 Deployment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Device
      • 5.5.3.7 Stage
      • 5.5.3.8 Component
      • 5.5.3.9 Deployment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Device
      • 5.5.4.7 Stage
      • 5.5.4.8 Component
      • 5.5.4.9 Deployment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Device
      • 5.5.5.7 Stage
      • 5.5.5.8 Component
      • 5.5.5.9 Deployment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Device
      • 5.5.6.7 Stage
      • 5.5.6.8 Component
      • 5.5.6.9 Deployment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Device
      • 5.6.1.7 Stage
      • 5.6.1.8 Component
      • 5.6.1.9 Deployment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Device
      • 5.6.2.7 Stage
      • 5.6.2.8 Component
      • 5.6.2.9 Deployment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Device
      • 5.6.3.7 Stage
      • 5.6.3.8 Component
      • 5.6.3.9 Deployment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Device
      • 5.6.4.7 Stage
      • 5.6.4.8 Component
      • 5.6.4.9 Deployment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Device
      • 5.6.5.7 Stage
      • 5.6.5.8 Component
      • 5.6.5.9 Deployment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Circassia Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Aimmune Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 DBV Technologies
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Allakos
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Kymab
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Astra Zeneca
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Amgen
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Teva Pharmaceutical Industries
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 GSK
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Regeneron Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Sanofi
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Novartis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Chiesi Farmaceutici
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 ALK- Abello
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Mabtech
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Genentech
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Boehringer Ingelheim
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Biogen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Alkermes
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Innovent Biologics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us